| Home > Publications Database > Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses. > Access to Fulltext |
DZNE-2026-00600
|
|||||||
| version 1 |
| ||||||
| Restricted | |||||||
DZNE-2026-00600 SUP
|
|||||||
| version 1 |
| ||||||